Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- 21 Regional Clinical Trials Networks Exchange Opinions with 40 Drug Firms: JMACCT
September 17, 2007
- Toho Pharm. Invests in Drug Wholesaler in China
September 17, 2007
- Iressa's Non-Inferiority to Docetaxel Proven for the First Time: AstraZeneca
September 17, 2007
- Litigation over Leuplin Invention Settled: Takeda
September 17, 2007
- R&D NEWS IN BRIEF
September 17, 2007
- Diovan Remains No. 1 for 4 Consecutive Months
September 17, 2007
- First Switch OTC Drug for Urinary Frequency for Women to Be Approved
September 17, 2007
- JA-Zenkouren Considers Collective Bargaining on Drug Prices
September 17, 2007
- Kyowa Hakko Launches Line of L-Citrulline Health Foods
September 17, 2007
- Blopress Maintains Top Position in 2nd Qtr: IMS Japan
September 17, 2007
- Hearings Completed for New Vision for Medical Devices Industry
September 17, 2007
- TOPICS／Seminar Aimed at Employment of Female MRs Attracts 300 Participants
September 17, 2007
- NEW PRODUCST
September 17, 2007
- BUSINESS NEWS IN BRIEF
September 10, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 10, 2007
- Zeria Licenses TM-411 from TMRC
September 10, 2007
- SURVEY／Many Patients Still Want Hospital-Based Doctors to Serve as Attending Physicians
September 10, 2007
- Takeda Begins PII Trial for TAK-536 for Hypertension
September 10, 2007
- TOPICS／Pharma Delegates Launches 2007/2008 Season
September 10, 2007
- JCL Bioassay to Start "Cold" MD Studies
September 10, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…